creators_name: Vella, SC
creators_name: Pai, NB
creators_id: vella@uow.edu.au
editors_name: Kakkilaya, Srinivas
editors_id: Kakkilaya BS
type: journale
datestamp: 2013-05-04 23:04:38
lastmod: 2013-05-04 23:04:38
metadata_visibility: show
title: Prevalence & Prescription: Prescribing Practices of Clozapine in Australia between 2005 & 2010
ispublished: pub
subjects: JOURNALS
subjects: OJHAS
full_text_status: public
keywords: Clozapine; Treatment-resistant schizophrenia; Prevalence rates; Australia
abstract: Clozapine is an anti-psychotic used to treat refractory schizophrenia. This study reviews the rates of clozapine prescription for refractory schizophrenia in a region of Australia and compares the prescribing patterns to the estimated prevalence rates of refractory schizophrenia in the region. Utilising a pharmacoepidemiological approach; the results indicated that only 8.4% of the individuals estimated to be suffering from refractory schizophrenia in the region were prescribed clozapine between 2005 and 2010, with only 4.1% continuing clozapine to the conclusion of the study.  In conclusion it is evident that clozapine is widely under-prescribed in this area of Australia.
date: 2012-04-15
date_type: published
publication: Online Journal of Health and Allied Sciences
volume: 11
number: 1(6)
publisher: BS Kakkilaya
refereed: TRUE
referencetext: 1.	Capuano B, Crosby IT, Lloyd EJ. Schizophrenia: Genesis, receptorology, and current therapeutics. Current Medicinal Chemistry. 2002;9:521-548.
2.	Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophrenia Bulletin. 1997;23(4):663-674.
3.	Semiz UB, cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, Balibey H, Algul A, Ates A. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2007;31:1330-1336. 
4.	Angermyer MC, Loffler W, Muller P, Schulze B, Priebe S. Patients’ and relatives’ assessment of clozapine treatment. Psychological Medicine. 2001;31:509-517.
5.	Wheeler A, Humberstone V, Robinson G. Outcomes for schizophrenia patients with clozapine treatment: how good does it get? Journal of Psychopharmacology. 2009;23(8):957-965.
6.	Kelly DL, Kreyenbuhl J, Buchanan RW, Malhotra AK. Why not clozapine? Clinical Schizophrenia. 2007;1:92-95.
7.	Henneen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophrenia Research 2005;73:139-145.
8.	Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophrenia Bulletin 1998;24(3): 381-390.
9.	Reznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, Weizman A. Myotoxicity and neurotoxicity during clozapine treatment. Clinical Neuropharmacology 2000;23(5):276-280.
10.	Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists attitude towards and knowledge of schizophrenia treatment. Journal of Psychopharmacology. 2010;24(7):965-971.
11.	Wheeler A, Humberstone V, Robinson G. Trends in anti-psychotic prescribing in schizophrenia in Auckland. Australasian Journal of Psychiatry 2006;14(2):169-174.
12.	Marder SR. Can clinical practice guide a research agenda? Schizophrenia Bulletin. 2002;28(1):127-129.
13.	Conley RR, Kelly DL, Lambert TJ, Love RC. Comparison of clozapine use in Maryland and in Victoria Australia. Psychiatric Services. 2005;56(3):320-323.
14.	Fayek M, Flowers C, Signorelli D, Simpson G. Psychopharmacology: underuse of evidence-based treatments in psychiatry. Psychiatric Services. 2003;54(11):1453-1456.
15.	Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry. 2002;37:55-61.
16.	Weinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA. Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund. Pharmacopsychiatry 2008;41:1-6.  
17.	Drew LRH, Griffiths KM, Hodgson DM. A five year follow-up study of the use of clozapine in community practice. Australian and New Zealand Journal of Psychiatry 2002;36:780-786.
citation:   Vella, SC and Pai, NB  (2012) Prevalence & Prescription: Prescribing Practices of Clozapine in Australia between 2005 & 2010.  [Journal (On-line/Unpaginated)]     
document_url: http://cogprints.org/8871/1/2012-1-6.pdf